

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

UTILITY PATENT APPLICATION TRANSMITTAL

Only for new nonprovisional applications under
37 C.F.R. 1.53(b)

Attorney Docket No.

1855.1052-025

First Named Inventor or
Application Identifier

Gregory J. LaRosa

Express Mail Label No.

EL551755199US

Title of
Invention

ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages **[60]**
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to microfiche Appendix
 - Background of the Invention
 - Summary of the Invention
 - Brief Description of the Drawings
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **[15]**
☒ Formal ☐ Informal
☐ Fig. of the Drawings for Publication ☐
4. ☐ Oath or Declaration/POA [Total Pages **[]**]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 C.F.R. 1.63(d))
(for continuation/divisional with Box 18 completed)
[NOTE Box 5 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior
application, see 37 C.F.R. 1.63(d)(2)
and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b, is
considered as being part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
[2] Pages
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & documents)
☒ Assignee - Millennium Pharmaceuticals, Inc.
 Cambridge, MA
9. ☐ 37 C.F.R. 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS
Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request (check parent application)
17. ☒ Other: Transmittal of Sequence Listing; Remarks;
Statement Pursuant to 37 C.F.R. §1.607(c)

18. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/121,781

Prior application information: Examiner: A. Salimi

Group Art Unit: 1648

19. CORRESPONDENCE ADDRESS

NAME	Lisa M. Treannie, Esq.				
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	Two Militia Drive				
CITY	Lexington	STATE	MA	ZIP CODE	02421-4799
COUNTRY	USA	TELEPHONE	(781) 861-6240	FAX	(781) 861-9540

Signature	<i>Lisa M. Treannie</i>	Date	7/3/01
Submitted by Typed or Printed Name	Lisa M. Treannie	Reg. Number	41,368

LMT/pdd
07/03/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregory J. LaRosa

Continuation Application of

Application No.: 09/121,781

Filed: July 23, 1998

For: Anti-CCR2 Antibodies and Methods of Use Therefor

Date: 7/3/01

EXPRESS MAIL LABEL NO. EL551755199US

REMARKS

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The above-captioned application is a continuation of application number 09/121,781 filed on July 23, 1998 to which priority is claimed under 35 U.S.C. §120.

The Specification has been amended as follows:

A related applications paragraph has been added as the first paragraph in the specification.

The appropriate ATCC Accession numbers for the biological deposits referenced in the application have been added.

The Specification, including the brief description of the drawings, has been amended such that the numbering of the drawings corresponds with the numbering of the formal drawings filed

07/03/01

cc961 U.S. PRO

05898513.070301

concurrently. No new matter has been added.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Treannie
Lisa M. Treannie
Registration No. 41,368
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 7/3/01

0989513-070301
FOE020" EFS86860

LMT/pdd
07/03/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregory J. LaRosa

Continuation Application of

Application No.: 09/121,781

Filed: July 23, 1998

For: Anti-CCR2 Antibodies and Methods of Use Therefor

Date: 7/3/01

EXPRESS MAIL LABEL NO. EL551755199US

STATEMENT PURSUANT TO 37 C.F.R. §1.607(c)

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In order for the Examiner to consider whether the claims of the subject application correspond exactly or substantially to the claim of a patent, Applicant hereby identifies Claims 1-21 of U.S. Patent No. 6,084,075 pursuant to 37 C.F.R. §1.607(c).

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Treannie

Lisa M. Treannie
Registration No. 41,368
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 7/3/01